Diabetic cure

The claim is mostly true, but with important caveats:

✅ What’s accurate:

• A Chinese research team at Shanghai’s Changzheng Hospital has reported a first-in-human stem-cell therapy that regenerated insulin-producing islet (β‑) cells in a patient with long-standing Type 2 diabetes (T2D)  .
• The procedure used the patient’s own blood-derived stem cells, converted into functional β‑cell–containing islets, and transplanted in July 2021  .
• Within 11 weeks, the patient became insulin‑independent, and roughly a year later had also stopped all oral diabetes medications  .
• Follow‑up data up to 33 months post-transplant showed sustained restored pancreatic function  .

⚠️ What’s still uncertain:

• This breakthrough has been reported in only one person so far  —far too early to call it a cure applicable to the broader diabetic population.
• It’s published in the scientific journal Cell Discovery, a well-regarded peer-reviewed platform  .
• These are early-stage results (akin to Phase 1), and larger clinical trials are needed to assess safety, reproducibility, durability, and scaling feasibility.

🔬 Verdict:

• Claim of reversal of Type 2 diabetes in a human via regenerating β‑cells is true, based on peer-reviewed early data.
• However, calling it a “cure” for everyone would be premature—this is a single-patient case study, not yet validated in larger trials

In a nutshell:

This is a genuine scientific milestone—a patient with long-standing Type 2 diabetes stopped all treatments and regained normal blood sugar levels thanks to stem cell–derived islet transplantation. But it remains an experimental proof-of-concept, not yet ready to end daily diabetic care routines for the broader community.